STOCK TITAN

Ionis Pharmaceuticals Inc - IONS STOCK NEWS

Welcome to our dedicated news page for Ionis Pharmaceuticals (Ticker: IONS), a resource for investors and traders seeking the latest updates and insights on Ionis Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ionis Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ionis Pharmaceuticals's position in the market.

Rhea-AI Summary
Ionis Pharmaceuticals, Inc. published its 2023 Corporate Responsibility Report, highlighting new strategic pillars and goals, U.S. approval of two Ionis-discovered medicines, and commitment to corporate responsibility. The report showcases Ionis' dedication to innovation, patient support, and sustainable operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Ionis Pharmaceuticals, Inc. (IONS) will be holding a live webcast on May 7th, 2024, at 11:30 a.m. Eastern Time to discuss its first quarter financial results for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
-
Rhea-AI Summary
Ionis Pharmaceuticals announces positive Phase 3 results for olezarsen in treating familial chylomicronemia syndrome, showing significant reduction in triglycerides and acute pancreatitis events, potentially offering a breakthrough treatment option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Ionis Pharmaceuticals, Inc. (IONS) will participate in several investor conferences in 2024, including the Needham Virtual Healthcare Conference, RBC Capital Markets Global Healthcare Conference, BofA Securities Health Care Conference, and Goldman Sachs Global Healthcare Conference. The presentations can be accessed via webcast on the Ionis website, with replays available within 48 hours.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
conferences
-
Rhea-AI Summary
Ionis Pharmaceuticals, Inc. (IONS) will host a webcast on April 8 at 10:00 a.m. Eastern Time to discuss olezarsen Phase 3 Balance study results in patients with familial chylomicronemia syndrome (FCS) presented at the 2024 American College of Cardiology Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.93%
Tags
-
Rhea-AI Summary
Ionis Pharmaceuticals, Inc. presents positive Phase 3 Balance results for olezarsen at ACC Annual Meeting, showcasing significant reductions in triglycerides and acute pancreatitis events in patients with FCS, a rare disease with no approved treatments in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.79%
Tags
Rhea-AI Summary
Ionis Pharmaceuticals, Inc. (IONS) announces positive results from a Phase 2 study of ION224, an investigational DGAT2 antisense inhibitor, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), achieving significant improvements in liver histologic improvement and MASH resolution. The study met its primary endpoint and key secondary endpoint, showcasing promising results in patients with advanced fibrosis. ION224 was safe and well-tolerated, offering a potential precision medicine opportunity for MASH patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
-
Rhea-AI Summary
Ionis Pharmaceuticals welcomes Kyle Jenne back to lead commercial strategy while Onaiza Cadoret-Manier departs for new opportunities. Ionis gears up for independent launches with core capabilities in place.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.86%
Tags
none
-
Rhea-AI Summary
Ionis Pharmaceuticals, Inc. (IONS) will participate in fireside chats at TD Cowen 44th Annual Health Care Conference and Stifel 2024 Virtual CNS Days. Investors can access live webcasts on the Ionis website with replays available within 48 hours.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
conferences
Rhea-AI Summary
Ionis Pharmaceuticals reports positive Phase 3 data, financial guidance for 2024, and upcoming regulatory decisions for WAINUA™
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
Ionis Pharmaceuticals Inc

Nasdaq:IONS

IONS Rankings

IONS Stock Data

6.08B
144.53M
0.86%
100.99%
6.53%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Carlsbad

About IONS

ionis pharmaceuticals, inc., located in the north san diego county city of carlsbad, was founded in 1989 to create advanced, novel medicines to treat complex and challenging diseases. we are the pioneer in the discovery and development of antisense drugs with more than 1300 patents. ionis is a challenging, motivating and rewarding environment designed to foster innovation and scientific excellence. our founding goals have changed little in over 27 years and our success is a direct result of our outstanding employees. we are interested in bringing together individuals with different skill sets into this creative environment to be part of a productive team. join us and experience our unique culture while you develop and expand your career. for more information about ionis and to apply for an open position, please visit our website: www.ionispharma.com.